Expert Interview
A Second View: Looking at the topline results from the LIBRETTO-531 study evaluating Retevmo versus cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic thyroid cancer (MTC)
Ticker(s): LLYInstitution: WUSTL
- Associate Professor of Medicine in Medical Oncology at Washington University School of Medicine
- Manages 250 patients with HNSCC.
- Research focused on human papillomavirus (HPV)-unrelated head and neck squamous cell carcinoma (HNSCC), advanced laryngeal squamous cell carcinoma, HNSCC, and advanced or metastatic soft-tissue sarcoma; clinical expertise in head and neck cancers.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
